Gilead Sciences Inc. (GILD)
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this year. The offer of $115 per share in cash represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of 20 February.
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with an equity value of $7.8 billion.
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Gilead Sciences, Inc. shares have risen more than 43% over the past year. I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-year to $4.2 billion in Q4. On the other hand, sales of Gilead's oncology franchise leave much to be desired, despite its numerous attempts to compete with Merck, Pfizer, and AstraZeneca.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
Focus on These 5 Stocks That Recently Hiked Dividends
NTES joins four peers in lifting dividends as resilient markets, rate-cut hopes and volatility spur investors toward steady income plays.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes
Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
